ReviewClinical reviews in allergy & immunology2014
Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.
Review in Clinical reviews in allergy & immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Immunophenotypic insights into diabetes heterogeneity: The role of CD25-expressing T cells in Ghanaian type 1 diabetes cohorts.Journal of translational autoimmunity · 2026Article
- Diabetes and Vitiligo.Diabetes care · 2026Article
- Association of Vitiligo With Autoimmune Disorders: A Bidirectional Two-Sample and Summary-Based Mendelian Randomization Study.Journal of cosmetic dermatology · 2025Article
- Article
- The role of cytokines and T-bet, GATA3, ROR-γt, and FOXP3 transcription factors of T cell subsets in the natural clinical progression of Type 1 Diabetes.Immunologic research · 2023Article
- Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1.International journal of molecular sciences · 2021Review
- Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes.Frontiers in immunology · 2021Observational
- A comprehensive integrated post-GWAS analysis of Type 1 diabetes reveals enhancer-based immune dysregulation.PloS one · 2021Article
- Role of inflammatory markers in corona virus disease (COVID-19) patients: A review.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Two to Tango: Dialogue between Adaptive and Innate Immunity in Type 1 Diabetes.Journal of diabetes research · 2020Review
- Mesh induced fibrosis: The protective role of T regulatory cells.Acta biomaterialia · 2019Article
- Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?Frontiers in immunology · 2019Review
- The impact of poor glycemic control on lipid profile variables in children with type 1 diabetes mellitus.Journal of education and health promotion · 2019Article
- Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases.Frontiers in pharmacology · 2018Review
- Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study.European radiology · 2017Article
- Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study.BMJ open · 2017Article
- miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.Cellular & molecular immunology · 2017Review
- Article
- The Bach Family of Transcription Factors: A Comprehensive Review.Clinical reviews in allergy & immunology · 2016Review
- Critical Link Between Epigenetics and Transcription Factors in the Induction of Autoimmunity: a Comprehensive Review.Clinical reviews in allergy & immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by the destruction of pancreatic β cells. Numerous studies have demonstrated the key role of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) in the development of T1DM. However, the changes in Treg expression and function as well as the regulation of these activities are not clearly elucidated. Most studies on the role of Tregs in T1DM were performed on peripheral blood rather than pancreas or pancreatic lymph nodes. Tissue-based studies are more difficult to perform, and there is a lack of histological data to support the role of Tregs in T1DM. In spite of this, strategies to increase Treg cell number and/or function have been viewed as potential therapeutic approaches in treating T1DM, and several clinical trials using these strategies have already emerged. Notably, many trials fail to demonstrate clinical response even when Treg treatment successfully boosts Tregs. In view of this, whether a failure of Tregs does exist and contribute to the development of T1DM and whether more Tregs would be clinically beneficial to patients should be carefully taken into consideration before applying Tregs as treatments in T1DM.
Indexed as
Identifiers
25086642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.